About Lipoxen
Lipoxen is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anti-cancer drugs. The company was founded by Professor Gregory Gregoriadis, PhD, DSc, in 1997, as a spin out from The School of Pharmacy at the University of London. In January 2006 Lipoxen was listed on AIM.
The Company is incorporated and registered in the UK under company number 3213174.
Our proprietary technologies
Lipoxen has developed a range of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Lipoxen's technologies include:
| PolyXen® |
Protein drug delivery |
| ImuXen® |
DNA, protein and polysaccharide vaccines |
| VesicALL® |
Anti-cancer drugs using liposomal entrapment |
Lipoxen outlicenses these proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.
Our new product candidates
Lipoxen is also developing its own range of proprietary product candidates, based on products already in the market and which incorporate these new technologies. Product candidates which are currently under development include:
| ErepoXen® |
Potential treatment to maintain the red blood cell population and prevent anaemia |
| StimuXen™ |
Potential treatment for neutropenia (a deficiency in white blood cells associated with myelosuppressive chemotherapy) |
| InferoXen ® |
Potential treatment for hepatitis C |
| SuliXen® |
Potential treatment for type II diabetes |
| LipoNeu™ |
Potential vaccine for streptococcus pneumoniae (a cause of meningitis in children and pneumonia in adults) |
| LipoTet™ |
Potential oral tetanus vaccine |
| HepaXen™ |
Potential hepatitis B vaccine |
| LipoRab™ |
Potential rabies vaccine |
| LipoTaxen® |
Potential anti-cancer drug |
Once these new products reach an appropriate stage of development, Lipoxen intends them to be made available to biopharmaceutical companies for clinical trials and commercialisation.
Our partners
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance. These partners include Amgen Inc., Genentech Inc., Genzyme Inc., Teva Pharmaceutical Industries Limited, the Serum Institute of India Limited and Baxter Healthcare Corporation.
The Company is not admitted to trading on any other exchange or trading platform.